Home Applications 213004 Application 213004
Type NDA
Sponsor REDHILL Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 TALICIA AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN CAPSULE, DELAYED RELEASE;ORAL 250MG;EQ 10MG BASE;12.5MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213004-001 TALICIA AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN 250MG;EQ 10MG BASE;12.5MG CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2019-11-01
Orange Book patents# Current patent rows page 1 of 1 · 7 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N213004-001 10238606 2034-02-12 Drug product 2019-11-25 N213004-001 11135172 2034-02-12 U-2660 Drug product 2021-10-07 N213004-001 11931463 2034-02-12 U-3866 Drug product 2024-04-04 N213004-001 9050263 2034-02-12 U-2660 Drug product 2019-11-25 N213004-001 9498445 2034-02-12 U-2660 Drug product 2019-11-25 N213004-001 9603806 2034-02-12 U-2660 Drug product 2019-11-25 N213004-001 11878011 2042-05-27 U-3816 2024-02-21
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 2 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N213004-001 NP 2022-11-01 N213004-001 GAIN 2027-11-01
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 42 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N213004-001 TALICIA 250MG;EQ 10MG BASE;12.5MG CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2019-11-01 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213004-001 TALICIA 250MG;EQ 10MG BASE;12.5MG CAPSULE, DELAYED RELEASE / ORAL RLD, RS 2019-11-01 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 7 · 244 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N213004-001 10238606 2034-02-12 Drug product 2019-11-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213004-001 11135172 2034-02-12 U-2660 Drug product 2021-10-07 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213004-001 11931463 2034-02-12 U-3866 Drug product 2024-04-04 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213004-001 9050263 2034-02-12 U-2660 Drug product 2019-11-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213004-001 9498445 2034-02-12 U-2660 Drug product 2019-11-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213004-001 9603806 2034-02-12 U-2660 Drug product 2019-11-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213004-001 11878011 2042-05-27 U-3816 2024-02-21 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N213004-001 10238606 2034-02-12 Drug product 2019-11-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213004-001 11135172 2034-02-12 U-2660 Drug product 2021-10-07 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213004-001 11931463 2034-02-12 U-3866 Drug product 2024-04-04 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213004-001 9050263 2034-02-12 U-2660 Drug product 2019-11-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213004-001 9498445 2034-02-12 U-2660 Drug product 2019-11-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213004-001 9603806 2034-02-12 U-2660 Drug product 2019-11-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213004-001 11878011 2042-05-27 U-3816 2024-02-21 c2088c7a36db…2026-09-14 22:38:34 2026-08 N213004-001 10238606 2034-02-12 Drug product 2019-11-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213004-001 11135172 2034-02-12 U-2660 Drug product 2021-10-07 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213004-001 11931463 2034-02-12 U-3866 Drug product 2024-04-04 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213004-001 9050263 2034-02-12 U-2660 Drug product 2019-11-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213004-001 9498445 2034-02-12 U-2660 Drug product 2019-11-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213004-001 9603806 2034-02-12 U-2660 Drug product 2019-11-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213004-001 11878011 2042-05-27 U-3816 2024-02-21 84e616aacf4f…2026-08-18 06:07:40 2026-07 N213004-001 10238606 2034-02-12 Drug product 2019-11-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213004-001 11135172 2034-02-12 U-2660 Drug product 2021-10-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213004-001 11931463 2034-02-12 U-3866 Drug product 2024-04-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213004-001 9050263 2034-02-12 U-2660 Drug product 2019-11-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213004-001 9498445 2034-02-12 U-2660 Drug product 2019-11-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213004-001 9603806 2034-02-12 U-2660 Drug product 2019-11-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213004-001 11878011 2042-05-27 U-3816 2024-02-21 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213004-001 10238606 2034-02-12 Drug product 2019-11-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213004-001 11135172 2034-02-12 U-2660 Drug product 2021-10-07 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213004-001 11931463 2034-02-12 U-3866 Drug product 2024-04-04 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213004-001 9050263 2034-02-12 U-2660 Drug product 2019-11-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213004-001 9498445 2034-02-12 U-2660 Drug product 2019-11-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213004-001 9603806 2034-02-12 U-2660 Drug product 2019-11-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213004-001 11878011 2042-05-27 U-3816 2024-02-21 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213004-001 10238606 2034-02-12 Drug product 2019-11-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213004-001 11135172 2034-02-12 U-2660 Drug product 2021-10-07 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213004-001 11931463 2034-02-12 U-3866 Drug product 2024-04-04 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213004-001 9050263 2034-02-12 U-2660 Drug product 2019-11-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213004-001 9498445 2034-02-12 U-2660 Drug product 2019-11-25 31067a03dcf5…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 46 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Talicia OMEPRAZOLE MAGNESIUM, AMOXICILLIN AND RIFABUTIN RedHill Biopharma Ltd 68c4e9dc-dbcf-4151-b6f7-5e4b9922b76f 2025-12-23 Warnings, Adverse reactions Exact identifier application applno (NDA): 213004 application number: NDA213004 ndc (product): 57841-1150
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 5 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 57841-1150 Talicia omeprazole magnesium, amoxicillin and rifabutin RedHill Biopharma Ltd NDA Current 57841-1150 Talicia omeprazole magnesium, amoxicillin and rifabutin RedHill Biopharma Ltd NDA Current 57841-1150 Talicia omeprazole magnesium, amoxicillin and rifabutin RedHill Biopharma Ltd NDA Current 57841-1150 Talicia omeprazole magnesium, amoxicillin and rifabutin RedHill Biopharma Ltd NDA Current 57841-1150 Talicia omeprazole magnesium, amoxicillin and rifabutin RedHill Biopharma Ltd NDA Current